FATE THERAPEUTICS INC Proceeds from Long-Term Debt Issued
FATE THERAPEUTICS INC (FATE) reported Proceeds from Long-Term Debt Issued of $15.00 million for the 12-month period ending 2017-12-31, per its 10-K filed 2020-03-02.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfLongTermDebt · last filed 2020-03-02
- FATE THERAPEUTICS INC proceeds from issuance of long-term debt for the quarter ending 2017-12-31 was $0.00.
- FATE THERAPEUTICS INC proceeds from issuance of long-term debt for the quarter ending 2014-12-31 was $10.00M.
- FATE THERAPEUTICS INC proceeds from issuance of long-term debt for fiscal 2017 was $15.00M.
- FATE THERAPEUTICS INC proceeds from issuance of long-term debt for fiscal 2014 was $20.00M.
- FATE THERAPEUTICS INC proceeds from issuance of long-term debt for fiscal 2011 was $3.40M.
| Period end | Proceeds from Issuance of Long-term Debt 3 month | Proceeds from Issuance of Long-term Debt 9 month | Proceeds from Issuance of Long-term Debt 12 month | Proceeds from Issuance of Long-term Debt 77 month | Proceeds from Issuance of Long-term Debt 80 month | Proceeds from Issuance of Long-term Debt 83 month |
|---|---|---|---|---|---|---|
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $15.00M 10-K · filed 2020-03-02 | ||||
| 2017-09-30 | $15.00M 10-Q · filed 2018-11-01 | |||||
| 2014-12-31 | $10.00M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $20.00M 10-K · filed 2017-03-16 | ||||
| 2014-09-30 | $10.00M 10-Q · filed 2015-11-03 | |||||
| 2014-03-31 | $6.40M 10-Q · filed 2014-05-13 | |||||
| 2013-12-31 | $6.40M 10-K · filed 2014-03-17 | |||||
| 2013-09-30 | $6.40M 10-Q · filed 2013-11-13 | |||||
| 2011-12-31 | $3.40M 10-K · filed 2014-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |